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Abstract:
Objective
Infantile spasms (IS) or West syndrome is a convulsive disease characterized
by brief, symmetric axial muscle contractions (neck, trunk, and/or extremities).
The therapy universally recognized as most effective in the treatment of IS,
is treatment with the adrenocorticotropic hormone (ACTH) or oral corticosteroids.
This therapy however has important side effects. Many studies have sought
to find alternative therapies with fewer side effects. Nitrazepam, it has been
proven, can be as effective as ACTH in controlling infantile spasms. The aim
of this study was to evaluate and compare the efficacy of Nitrazepam and
ACTH on the treatment of infantile spasms.
Materials & Methods
 This randomized controlled clinical trial, enrolled sixty patients with newly
diagnosed and previously untreated IS; diagnosis was made based on the
criteria of The International Classification of Epilepsies of the International
League Against Epilepsy (ILAE). Prior to treatment, all patients underwent
Electro encephalo graphs (EEGs) and CT scans. Patients were randomized to
receive 0.5-1 mg/kg Nitrazpam (NZP) in three daily doses or 40 IU Depot
ACTH in a single morning dose. Complete cessation of spasms was considered
to be as optimal response.
Results
Of the sixty patients studied, 24 (40%) were girls and 36(60%) were boys. All
patients in the both groups were matched for age and sex.There were no
differences between the both groups regarding age and sex (non-significant).
Following treatments, at the end of the 6-week duration therapy, optimal
response (Cessation of spasms) was obtained in 19 (63%) patients of NZP
group and 9 (30%) patients of ACTH group, (P<0.05). ACTH side effects were
more pronounced than those of NZP; Most patients in ACTH group, developed
cushingoid features (moon face 93%, weight gain 100%)(P<0.05); a few
patients,all from the ACTH group, developed hypertension (P<0.05). The side
effects of nitrazepam were drowsiness 33%, hypotonia 10%, infection 20%,
and hypersalivation 93%. EEG anomalies had disappeared in 47% of NZP
patients and in 30% of ACTH patients (P>0.05).
Conclusion
 This study supports the belief that NZP offers an effective and possibly safer
therapy than ACTH, for the management of IS and that the therapeutic
response, if imminent, can be detected within 4-6 weeks of treatment. Clinicians
should consider using NZP as a first-line therapy for IS.
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Introduction
Infantile spasms (IS), a type of seizure that was first
described by West in 1841, who witnessed the epileptic
phenomenon in his own son(1). Infantile spasms or the
West syndrome is a convulsive disease that is
characterized by brief, symmetric axial muscle
contractions (neck, trunk, and/or extremities). Most cases
involve flexors and extensors, but either of the two may
be involved independently(2). IS, as the name implies,
occurs most often during the first year of life, affecting
one in every 2000-4000 infants(3-5). The condition
responds poorly to most conventional treatments, with
the outcome being frequently unfavorable in terms of
seizure control and cognitive development (6-10). Most,
but not all, patients with this disorder show severe EEG
abnormalities; this pattern was originally referred to as
hypsarrhythmia by Gibbs and Gibbs(11). Cases with
known etiology or signs of brain damage preceding the
spasms are classified as symptomatic; those without
known etiology or signs of brain damage are considered
cryptogenic. Prognosis is generally poor. The therapy
universally recognized as most effective in the treatment
of IS, is the adrenocorticotropic hormone (ACTH) or
oral corticosteroids(12). Steroids in the form of natural
ACTH, synthetic ACTH, tetracosactide, prednisolone,
and hydrocortisone have remained the first line of
treatment for IS(13-15).  However, this therapy has
important side effects and cannot be continued for >40-
60 days. Many studies have sought to find alternative
therapies with fewer side effects(16-23). Hormone therapy
is not effective in newborns with neurologic disorders
and congenital cerebral anomalies. It has been shown
that Na-Valporate (100mg/kg/day) although effective in
about 70% patients, may cause liver damage(7).
Nitrazepam (NZP), clonazepam, chlorazepate, and
clobazam are the benzodiazepines that have been known
to have efficacy in infantile spasms. In 1973, Vasella et
al(24) reported that 38% of patients on clonazepam had
reduced spasms; however, no efficacy was demonstrated
in the study by Mimaki et al(25). Also, no effects of
clobazam were found in another study conducted in
1986(19). The only drug known to have been as effective
as ACTH in controlling infantile spasms, is
nitrazepam(17). The aim of this study was to evaluate
and compare the efficacies of Nitrazepam and ACTH in
the treatment of infantile spasms.
Materials & Methods
In this randomized controlled clinical trial, sixty patients,
aged between 2 and 24 months (at onset of symptoms),
with newly diagnosed and previously untreated IS, were
enrolled between 1999 and 2000. This study was not
designed as a double blind clinical trial because ACTH
was a parentral and NZP was an oral agent. Diagnosis
was made based on the criteria of The International
Classification of Epilepsies of the International League
Against Epilepsy (ILAE)(22). All patients underwent
EEG recording and brain CT scan at initiation of treatment.
Patients were randomized into 2 groups, to receive 0.5-
1 mg/kg NZP in three daily doses or 40 IU Depot ACTH
in a single morning dose. If after 14 days of therapy,
spasms did not disappear, or if intolerance was present,
the therapy was discontinued. Complete cessation of
spasms was considered to be an optimal response
(complete treatment). Basic workup included CBC diff
(Complete Blood Count), BS (Blood Sugar), UA, (Urine
Analysis), serum amino acids, and thyroid function tests.
Metabolic evaluation and sepsis workup were also done
for all patients. Blood pressure, drowsiness, and any
other adverse drug effects were recorded on the first day
of admission, and also at 4th and 6th weeks of therapy.
Results
Of the sixty patients studied, 24 (40%) were girls and
36(60%) were boys. There were no differences between
the two groups regarding sex and age (P>0.05)(Table 1).
Of the thirty infants in each group, 6 (20%) had spasms
classified as cryptogenic. In the remaining 24 (80%)
patients, spasms were symptomatic. The clinical forms
of convulsion included flexion (58%), extension (10%),
and mixed (32%). Main causes of symptomatic IS types
were hypoxic ischemic encephalopathy, brain
malformation (cortical dysplegia, migration disorder,
fetal infection, tuberous sclerosis, etc.  Computed
Tomography (CT) scan was abnormal in 49 (82%) patients
(Table 1).
At the end of the 6th week of therapy, an optimal response
(cessation of spasms) was obtained in 19 (63%) patients
of the NZP group and 9 (30%) patients of the ACTH
group (P<0.05) (Table 2).
Overall side effects were drowsiness (25%), weight gain
(53.3%), moon face (46.7%), infection (21.7%),
hypertension (11.7%), and hypotonia (6.7%).
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The side effects seen in ACTH patients were more
pronounced than those of the NZP group. Most ACTH
patients developed cushingoid features (moon face 93%,
weight gain 100%) (P<0.05), and a few in this group also
developed hypertension (P<0.05) (Table 3). EEG variations
were analyzed after 6 weeks of therapy in both groups,
showing that in 47% of NZP patients and in 30% of
ACTH patients, these abnormalities had disappeared
(P>0.05)(Tables 4,5).
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Discussion
The treatment of infantile spasms is, at best, empirical
because the underlying pathophysiology of the disorder
and the precise mechanisms of action of drugs used for
it, are not fully understood(2). Steroids and ACTH have
been known to be effective in the treatment of infantile
spasms for more than 40 years(4,5,26,27). The role of
surgical treatment for IS has not been fully defined(28).
 In a recent extensive review, Snead and Chiron(12)
confirmed that therapy with ACTH and steroids is the
most effective in treating infantile spasms, with success
rates varying from 50% to 90%. Corticosteroids are also
effective. Prednisolone (2 to 10 mg/kg per day),
dexamethasone (0.3 to 0.5 mg/kg per day) and
hydrocortisone (5 to 20 mg/kg per day) are most
commonly recommended(29). The percentages vary
among different patient series depending on the//in
relation to etiology (with better response among
cryptogenic cases), dosage and duration of treatment,
and side effects.
A major disadvantage of treatment with ACTH and
steroids is the relatively high incidence of side effects
(37% in our patients) such as irritability, agitation,
increased blood pressure, increased body weight, diarrhea,
and susceptibility to infections; moreover, because of
the risk of adverse effects, these drugs should be used
only for relatively short periods of time(2). Many other
antiepileptic drugs have been used to treat IS, and with
the possible exception of BZDs and valproic acid (VPA),
results have been poor(19-22). Vigabatrin is especially
useful when the spasms are caused by tuberous
sclerosis(30). Nitrazepam, clonazepam, chlorazepate,
and clobazam are the benzodiazepines that have
demonstrated efficacy in infantile spasms. In 1973,
Vasella et al(24) reported that 38% of patients on
clonazepam had reduced spasms; however the study by
Mimaki et al, showed no such efficacy(25). Also, in
another study conducted in 1986, no effects using
clobazam were found(19). In a double-blind, controlled
study, only nitrazepam was proved to be as effective as
ACTH in controll ing infantile spasms(17).
We conducted this randomized study to compare using
NZP and ACTH as first-line treatments for IS. Patients
were selected randomly, and the two groups-one treated
with NZP and the other with ACTH-were sufficiently
similar/carefully matched. The success rate (complete
disappearance of spasms) of the NZP group was higher
than that seen in the ACTH group (63% VS 30%); NZP
also produced fewer side-effects. Most patients in the
ACTH group, developed cushingoid features (moon face
93%, weight gain 100%). NZP side effects were
drowsiness 10 (33%), hypotonia 3 (10%), infection 6
(20%), and hypersalivation 28 (95%). In a study
conducted by Dreifuss F et al fifty-two patients were
enrolled in a four-week randomized multicenter study
comparing nitrazepam and corticotropin in the treatment
of infantile spasms; results of both treatments despite
significantly reducing spasm frequency from that
documented at baseline, showed more qualitatively severe
adverse effects encountered among the patients treated
with corticotrophin(17).
Conclusion
In conclusion, this study supports the belief that NZP
offers an effective and possibly safer therapy for the
management of IS than does ACTH, and that a therapeutic
response, if imminent, can be detected within 4-6 weeks
of treatment. It is recommended that clinicians should
consider using NZP as a first-line therapy for IS.
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